Design Therapeutics (DSGN) FCF Margin (2020)
Design Therapeutics recorded quarterly FCF Margin of 8660.61% in Q4 2020, up 6.83% quarter-over-quarter from 9295.0% in Q3 2020.
Design Therapeutics' FCF Margin history runs 1 years deep, the most recent figure standing at 8660.61% for Q4 2020.
- In Q4 2020, FCF Margin changed N/A year-over-year to 8660.61%; the TTM figure through Dec 2020 stood at 3842.04% (changed N/A YoY), while the FY2020 annual figure was 3869.47%, changed N/A from the prior year.
- FCF Margin came in at 8660.61% for Q4 2020 at Design Therapeutics, up from 9295.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1872.54% in Q1 2020 to a low of 9295.0% in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -8,660.61% |
| Sep 30, 2020 | -9,295.00% |
| Jun 30, 2020 | -4,216.13% |
| Mar 31, 2020 | -1,872.54% |